Published in Cancer Weekly, June 29th, 2004
"Our data suggest that clinician assessment alone should not be relied upon in reporting side effects in chemotherapy clinical trials," said Tomasz M. Beer, MD, director of the prostate cancer program in the OHSU Cancer Institute and principal investigator of the study. "If verified, these findings strongly suggest that new tools for patient reporting of symptoms should be developed for use in chemotherapy clinical trials."
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly